Robert (Bob) Coffey

SPORE grant funds $12 million for colorectal cancer research

SPORE grants are highly sought after because they show that a cancer center demonstrates scientific excellence, promotes collaboration, maintains robust research programs and merits substantial funding.

Grant funds quest to expand immunotherapy efficacy for colorectal cancer  

The study seeks to understand the mechanisms of colorectal cancer and builds on recent Vanderbilt research.

Ken Lau, PhD, left, and Bob Coffey, MD, have made several important discoveries about colorectal cancer that are aiding the search for new, more effective therapies. (photo by Erin O. Smith)

Colorectal cancer ‘cartography’ reveals an avenue to improved immunotherapy

Vanderbilt University Medical Center researchers have discovered why most colorectal tumors escape detection and destruction by the body’s immune system.

Bob Coffey, MD

Vanderbilt research presented at Cancer Moonshot meet

Vanderbilt Colorectal cancer expert Bob Coffey, MD, was recently invited to present his research to representatives of President Joe Biden’s reignited Cancer Moonshot initiative.

A ‘supermere’ method for biomarker discovery

Vanderbilt researchers have developed a method for isolating extracellular vesicles and nanoparticles — a complex transport system involved in health and disease — which will improve biomarker discovery and the identification of therapeutic targets.

x-ray of stomach

New prognosis predictor and target for gastric cancer

The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.

1 2 3